New platform for simple and rapid protein-based affinity reactions

Kei Kubota1,2, Takuya Kubo1, Tetsuya Tanigawa1,3, Toyohiro Naito1 & Koji Otsuka1

We developed a spongy-like porous polymer (spongy monolith) consisting of poly(ethylene-co-glycidyl methacrylate) with continuous macropores that allowed efficient in situ reaction between the epoxy groups and proteins of interest. Immobilization of protein A on the spongy monolith enabled high-yield collection of immunoglobulin G (IgG) from cell culture supernatant even at a high flow rate. In addition, immobilization of pepsin on the spongy monolith enabled efficient online digestion at a high flow rate.

A variety of antibody-based medicines have been approved in recent years1,2. These products have high annual returns due to their high selectivity toward their target antigens, relatively low levels of side effects, and stability in vivo; in addition, these medicines can be produced using standard cell culture procedures3–7. To obtain a high-quality antibody medicine at low cost, it is necessary to select highly productive cells, optimize the culture conditions, and develop an efficient purification method. To evaluate the productivity of a system for biosynthesis of an antibody, especially of the immunoglobulin G (IgG) subtype, a chromatographic system using a protein A immobilized column is often employed for selection and optimization of the cell culture. In order to process a large number of samples, it is necessary to perform rapid optimization using high-throughput chromatography8,9. Indeed, for certain antibodies, more than 100 kg is required at the clinical investigation stage10–12. Usually, separation media in which protein A is immobilized onto a crosslinked-agarose adsorbent are used for the analysis and purification of an antibody12–15 as a suitable separation antibodies16–19. However, as for currently available separation media, elution throughput is often limited, resulting in an inefficient optimization of purification and productivity. Furthermore, the expense of such adsorbents (30-fold higher than other typical adsorbents) and the difficulty of column packing contribute to the high final price of antibody-based medicines20–22. Therefore, there is an urgent demand for new separation media that can facilitate higher throughput and lower cost.

To achieve high throughput and low cost, monolithic materials with continuous three-dimensional (3D) structures are advantageous23–25. For purification of biomolecules, the monolithic structure is suitable for rapid reactions because the flow-through pores are integrated with the skeleton26–31. In a typical monolith, silica- or polymer-based materials are prepared by sol–gel reaction and/or phase separation. Accordingly, the control of pore size, especially for larger pore (>10 μm), scale up in column size, and packing to columnar tubes are not easy. Instead of these typical monoliths, we proposed using a sponge-like material or spongy monolith as a novel separation medium32, 33. The spongy monolith is prepared simply by blending a thermoplastic resin above its melting temperature. In this study, we prepared a novel spongy monolith consisting of poly(ethylene-co-glycidyl methacrylate) (PEGM). After the monolith was packed into a column, protein A was immobilized onto the media in situ, and the affinity reaction was quantitatively examined and validated under high-throughput conditions. In an additional application of the new platforms, we immobilized the digestive enzyme pepsin onto the spongy monolith and performed online flow digestion of an antibody, and then determined the primary structure of the antibody from the peptide fragments.

Results and Discussion

In this study, we prepared a novel spongy monolith consisting of poly(ethylene-co-glycidyl methacrylate) (PEGM). After the monolith was packed into a column, protein A was immobilized onto the media in situ, and the affinity reaction was quantitatively examined and validated under high-throughput conditions. In an additional application of the new platforms, we immobilized the digestive enzyme pepsin onto the spongy monolith and performed online flow digestion of an antibody, and then determined the primary structure of the antibody from the peptide fragments.

As shown in Fig. 1, a PEGM spongy monolith (PEGM-SpM) was successfully prepared with the expected morphology. In brief, the average pore size of the prepared PEGM-SpM was ~10 μm, as determined by mercury
The PEGM-SpM was packed into a stainless-steel column by a simple method (Supplementary Fig. 2) similar to that used in our previous study. After the column was conditioned with methanol and water, a protein A solution (1.0 mg mL$^{-1}$ in PBS) was passed through the column, and then incubated at 37 °C for 16 h after both ends of the column were sealed. No morphological alteration was observed following the protein A modification (Supplementary Fig. 3). To confirm the effect of the modification, we then analyzed the column (ProA-SpM) by liquid chromatography (LC). As shown in Fig. 2(a), IgG-1 was strongly retained on the original PEGM-SpM via hydrophobic interaction in a typical reversed-phase LC (RPLC) mode. On the other hand, the ProA-SpM exhibited significantly less hydrophobic interaction, resulting in faster elution of IgG-1. A similar phenomenon was observed when BSA was used as a solute (Supplementary Fig. 4). These results indicated that protein A effectively covered the skeleton surface of the monolith, dramatically suppressing non-selective hydrophobicity. Next, we confirmed the affinity of the ProA-SpM via simple pH-gradient LC, which is commonly employed to evaluate protein A-immobilized columns because the interaction between protein A and IgG occurs only at pH > 7. The resultant chromatograms are summarized in Fig. 2(b). As expected, IgG-1 was selectively retained on the ProA-SpM and released by a one-step pH gradient. By contrast, BSA was quickly eluted without any retention.

Figure 1. Protein A immobilized spongy monolith (ProA-SpM). Physical appearances of Pro-SpM including primary materials, a molded item, and a packed column.

Figure 2. UV Chromatograms of IgG and BSA on the PEGM-SpM and ProA-SpM. (a) Reversed-phase chromatograms of IgG-1 with the PEGM-SpM and ProA-SpM. (b) Affinity separation of IgG-1 by a stepwise pH gradient. (c) A relation between the injected amount of IgG-1 and the peak area with the ProA-SpM.
and PEGM-SpM adsorbed IgG-1 due to its high hydrophobicity. Additionally, another IgG family member, IgG-2, was also effectively separated on the ProA-SpM (Supplementary Fig. 5). In a simplified validation, we injected various amounts of IgG-1 into the ProA-SpM, and found that the linear range of peak area was at least 1.0–250 µg (Fig. 2.(c)). In addition, we evaluated the accuracy by continuous analyses (n = 6), and estimated the relative standard deviation (RSD) as 0.7%. According to these results, this simply prepared ProA-SpM column had affinity similar to that of commercially available protein A-immobilized columns.

To be most useful, an affinity column must have abundant adsorption capacity for the ligand(s) of interest. To evaluate the maximum adsorption capacity due to immobilized protein A, we performed a frontal analysis, a method commonly utilized to evaluate capacity by LC34, 35, of both our column and a commercially available protein A-immobilized column (ProA-Column). This analysis revealed that the densities of immobilized protein A in the ProA-SpM and ProA-Column were 1.0–4.2 nmol g⁻¹ and 5–21 nmol g⁻¹, respectively (Supplementary Fig. 6).

Although the density of immobilized protein A was slightly lower in the ProA-SpM, the adsorption capacity for IgG-1 was comparable between the two columns (0.31 mg for the ProA-SpM and 0.32 mg for the ProA-Column). Therefore, our ProA-SpM had sufficient capacity to serve as an affinity column for the effective separation of IgG.

The most important advantage of the spongy monolith is its potential for high-throughput elution. To evaluate this feature, we carried out a similar affinity separation using IgG-1 as the solute under various flow rate conditions; the results are summarized in Fig. 3. When the ProA-Column was utilized at a higher flow rate, the flow-through fraction was presented in front of the solvent peak, as shown in Fig. 3(a). By contrast, the ProA-SpM allowed higher recovery, even at a high flow rate. Figure 3(c) shows the chromatograms for both the ProA-Column and ProA-SpM at a flow rate of 9.0 mL min⁻¹. Obviously, the collected and flow-through peaks were completely different from each other. The backpressure and recovery of IgG on the columns at each flow rate are summarized in Fig. 4(a) and (b), respectively. For the ProA-SpM, both backpressure and recovery were superior to those of the ProA-Column. A potential reason for these significant differences, especially in recovery at a high flow rate, is that the affinity interaction between a protein-based ligand and an antibody under a higher flow rate is generally not effective in a column in which spherical and porous beads are packed, due to the lower accessibility caused by slower mass transfer. Usually, in an LC analysis, the van Deemter equation (1)36 is employed.
to determine the plate height, $H$, which is defined as diffusion per column length and directly contributes to the separation efficiency:

$$H = A d_p + (B D_m) / u + (C d^2_p / u) / D_m$$  \[1\]

Here, $d_p$, $D_m$, and $u$ are the diameter of the packed particle, diffusion coefficient of the solute, and linear velocity, respectively, and $A$, $B$, and $C$ are constants corresponding to eddy diffusion, longitudinal diffusion, and mass transfer, respectively. Under higher linear velocity, mass transfer is usually predominant, resulting in low separation efficiency. For interactions among macromolecules (e.g., protein–protein interactions), slow mass transfer may provide fewer chances for encounter; thus, most of the IgG was eluted without interaction at high flow rates on the ProA-Column. On the other hand, the spongy monolith contains only macro-size flow-through pores, and protein A should be immobilized only on the surface of the monolithic skeleton. Therefore, we anticipated that the ProA-SpM would allow effective interaction between protein A and IgG-1. Additionally, the linearity of recovery at a higher flow rate (9.0 mL min$^{-1}$) is similar to that at a lower flow rate (Supplementary Fig. 7).

Furthermore, we investigated the ruggedness of the ProA-SpM. As a result of 100 times repeated analyses with IgG under 9.0 mL min$^{-1}$, the RSDs of the retention time and recovery of IgG were estimated as 0.45% and 0.41%, respectively. Also, the recovery of IgG was kept over 99% even after washing with 0.1 M aqueous NaOH (5 times), which is commonly used as an evaluation for the ruggedness of affinity columns. These results suggested that the ProA-SpM had enough ruggedness as an affinity column. According to these results, we anticipate that the ProA-SpM could be used as a novel affinity separation medium for high-throughput purifications.

To demonstrate purification of IgG from cell culture samples, we used the ProA-SpM. Cell culture supernatant treated using typical procedures was separated with a simple pH gradient using a variety of flow rates. Then, the peak likely to contain IgG was manually fractionated, and the chromatograms of free supernatant and a standard IgG are shown in Fig. 5(a). To confirm the presence of IgG in the fraction, the collected sample was analyzed by authentic RPLC with time-of-flight (TOF) mass spectrometry (MS) (TOF-MS), which is usually employed for the proteins separation using a reversed-phase column with MS detection. As shown in the obtained chromatograms (Supplementary Fig. 8) generated by UV detection, both the supernatant and the first fraction contained a major peak and a few minor peaks, whereas the collected fraction clearly contained only one peak, which corresponded to the standard IgG peak. A comparison of total ion chromatograms is provided in Fig. 5(b). Similar to the UV chromatograms, the collected sample exhibited a clear peak without any other minor peaks. After deconvolution of the original MS results, all the peaks from the original supernatant could be assigned, and the observed MS numbers are summarized in Table 1. In addition, the MS spectra of each peak are described in Supplementary Fig. 9. These results indicate that the collected fraction contained the selectively separated IgG moiety from the natural cell culture sample. Finally, the concentration of IgG in the supernatant of the cell culture was estimated as 0.42 mg mL$^{-1}$. Thus, we successfully demonstrated affinity separation based on the protein A–IgG interaction at high throughput using the newly developed spongy monolith. The method exhibited a good reproducibility and efficient recovery over a wide range of concentrations.

As mentioned above, the newly developed spongy monolith was suitable for a high-throughput affinity reaction. Because the immobilization of the proteins was based on a simple reaction with epoxy groups in the monolith, we believe that this material could be used for a variety of protein-based reactions. To explore this idea further, we carried out high-throughput online digestion using a digestive enzyme, pepsin. The immobilization of pepsin was performed successfully by a method similar to the one used for protein A. Pepsin is an aspartic protease that cleaves peptide bonds between hydrophobic and preferably aromatic amino acids, such
as phenylalanine, tryptophan, and tyrosine. In this evaluation, an antibody solution was introduced into the
pepsin-immobilized spongy monolith (Pep-SpM), and the eluted fraction was analyzed by LC–MS. For compar-
ison, samples in a simple solution containing pepsin and the antibody were also analyzed to confirm the cleaved
peptides. The UV chromatograms are summarized in Fig. 6. As expected, longer reaction in solution yielded
larger peptide fragments. On the contrary, in online digestion with the Pep-SpM, the peptide fragments were
much larger, even though a faster flow rate ($100 \text{ mL h}^{-1}$) was employed. When a slower flow rate ($10 \text{ mL h}^{-1}$)
was used, the detected peaks were almost the same as those in solution samples treated for 150 min. The numbers
of peptides detected in LC–MS, as a function of the number of amino acids and elution time, are summarized
in Fig. 7. Both figures demonstrate that a slower flow allowed for more extensive digestion. These results clearly
showed that effective cleavage occurred in the Pep-SpM. To confirm the sequence of each peptide, a quantitative
analysis was also carried out. The theoretical alignment of amino acids in the antibody and the theoretical pep-
sin digestion fragments (digestion sites: N terminal, F, I, M, Y, W; C terminal, C, D, E, F, L, M, T, W, Y) were
compared against results generated by the PepFinder 2.0 based on the LC–MS data. All assignment data are sum-
marized in Supplementary Table 1. Coverage for the primary amino acid alignment, as determined from those
results, is shown in Table 2. In both elution flows, all 213 residues in the light chain were detected. Additionally,
coverage of the heavy chain corresponded to the flow speed; i.e., a slower flow provided higher coverage. These
results also supported the idea that efficient online digestion occurred in the Pep-SpM. Finally, we showed that the
reproducibility of the online digestion was satisfactory at both flow rates, as shown in Fig. 8 and Supplementary
Fig. 10. All these results indicate that the spongy monolith can be used for the effective online digestion.

| Sample                          | Peak No. | Retention Time (min) | Observed mass (Da) |
|---------------------------------|----------|----------------------|--------------------|
| Standard IgG                    | 1        | 15.35                | 149207             |
|                                 | 2        | 14.81                | 23382              |
|                                 |          |                      | 101380             |
|                                 |          |                      | 125840             |
| Supernatant (original)          | 1        | 15.46                | 149204             |
|                                 | 2        | 14.93                | 23384              |
|                                 | 3        | 14.00                | 46894              |
|                                 | 4        | 12.18                | 23567              |
|                                 | 5        | 7.15                 | 11666              |
|                                 | 6        | 5.99                 | —                  |
| Fraction 2 (IgG fraction from ProA-SpM) | 1        | 15.61                | 149208             |
| Fraction 1 (flow through fraction from ProA-SpM) | 3        | 13.99                | 46893              |
|                                 | 4        | 12.21                | 23566              |
|                                 | 5        | 7.21                 | 11677              |
|                                 | 6        | 6.14                 | —                  |

Table 1. Peak identifications from a protein A load sample. Fractions 1 and 2 were collected from the
separation (Fig. 1(j)) from the front and back peaks, respectively. The peaks are corresponding to Fig. 1(k). The
observed mass was estimated by a deconvolution of multi ions with MaxEnt1.

**Figure 6.** Online digestion of a recombinant human IgG1 antibody with the Pep-SpM. UV chromatograms of
the digested antibody in solution or online with the Pep-SpM.
Conclusion
In summary, we proposed a new platform for protein-based affinity reaction. A spongy monolith containing epoxy groups was effectively used in affinity separation with protein A and digestion with pepsin. Both results demonstrated the utility of the new platform for rapid-flow affinity reactions. We believe that this new platform will be useful for variety of protein-based reactions with rapid flow rates and low costs. Additionally, the platform can be easily scaled up, and we anticipate that future efforts will contribute to purification of antibody-based medicines at the plant level.

Methods
Preparation of a spongy monolith. 35 w% of poly(ethylene-co-glycidyl methacrylate) (PEGM), in which glycidyl methacrylate of 8% is contained, 52 w% of pore templates (pentaerythritol), whose particle size in diameter was classified around 10 μm, and 7 w% of auxiliary of pore templates (poly(oxyethylene, oxypropylene))...
triole were melted at 130 °C and homogeneously kneading. The resulting material was extruded as a columnar shape at 130 °C. The columnar material was immediately cooled in water to obtain the stick like material. After cooling, the material was washed in water under an ultrasonication to remove water-soluble compounds. At this stage, water-soluble compounds functioned as the pore templates. The porosity of the spongy monolith calculated by a void volume on LC was 65% and the diameter of its cross section across its entire length was 4.8 mm. (PEGM-SpM).

**Packing of a spongy monolith.** For packing spongy monoliths in a stainless steel column, we utilized an empty column with an internal diameter of 4.6 mm (Supplementary Fig. 2). The diameter of the spongy monolithic column was greater than the internal diameter of the empty column (4.6 mm). Nevertheless, the elasticity of the spongy monolith material facilitated the packing. The procedure for packing was as follows: One end of the spongy monolith was compressed with a thermal shrinkage tube at 120 °C. After cooling, the shrinkage tube was removed; and the diameter of the compressed end of the spongy monolith was reduced less than 4.6 mm. After macerating the spongy monolith into ethylene glycol as a lubricity agent, the shrunk portion of the spongy monolith was inserted into the empty column and pulled from the other end, until the non-shrunk portion completely filled the column. Finally, the excess portion of the spongy monolith was cut and the column end module was connected. At this point, the shrunk end of the spongy monolith was completely cut and only the portion of the material with the initial diameter was packed into the column. Then, the prepared column was connected to a pump of LC for continuous elution. The mixture of methanol/water was eluted to the column for further washing to remove the pore templates and the homogenization of the packing condition.

**Preparation of a protein A immobilized column.** Phosphate buffered salts (PBS) solution was prepared with a PBS tablet into pure water of 100 mL (9.57 mM, pH 7.5). Pierce Recombinant Protein A of 5 mg was dissolved in the PBS solution of 5 mL. For conditioning the column, acetonitrile (MeCN) and pure water were passed through the PEGM-SpM at room temperature for 5 mL in each solvent. The protein A solution (1 mg mL⁻¹) was fulfilled into the PEGM-SpM completely, and then the column was incubated at 37 °C for 16 h. The completed column was washed with pure water for 1 h at 1 mL min⁻¹. (ProA-SpM).

**Preparation of a pepsin immobilized column.** Pepsin of 15 mg was dissolved into 5 vol% formic acid aqueous solution of 5 mL. For conditioning the column, MeCN and pure water were passed through the PEGM-SpM at room temperature for 5 mL in each solvent. The pepsin solution (3 mg mL⁻¹) was fulfilled into the PEGM-SpM completely, and then the column was incubated at room temperature for a week. The completed column was washed with 5 vol% formic acid aqueous solution for 1 h at 1 mL min⁻¹. (Pep-SpM).

**Conditions for RPLC.** For RPLC evaluations, a linear gradient was employed using 0.1 vol% trifluoroacetic acid (TFA) aqueous solution (A) and 0.1 vol% TFA in MeCN at 1.0 mL min⁻¹ under 40 °C. The gradient condition was utilized at 100% A to 100% B for 20 min, and 100% B for 20 to 30 min. For an affinity separation of the ProA-SpM, a 50 mM phosphate buffer with 150 mM NaCl pH 7.5 (A) and pH 2.5 (B) was employed at 25 °C. Regarding Fig. 1(b), a linear gradient was utilized at 100% A (0 to 5 min), 100% A to 100% B (5 to 15 min), and 100% B (15 to 25 min). For the other figures, the stepwise gradient was employed. The condition at 1.0 mL min⁻¹ was 100% A (0–2.4 min) and 100% B (2.41 to 9.6 min). The gradient conditions were optimized in response to the flow rate.

**Fractionation and determination of IgG from cell culture.** To know the possibility for the affinity separation with the ProA-SpM, the real sample was utilized for the separation. Protein A load sample, which was obtained just by simple filtration with membrane filter (0.2 μm) to remove the cells, was directly injected into the ProA-SpM with the same conditions as above. The peak of the seemed to IgG was manually collected (Fraction 2) and the flow through fraction was also collected (Fraction 1). Both fractions, the original supernatant, and a standard IgG were analyzed by LC equipped with an electrospray ion source set in the positive ion mode for the m/z of 1000 to 4000. The parent molecular weights were estimated by a deconvolution of multi ions with MaxEnt139, 40 (Waters).

**Online digestion of an antibody by the Pep-SpM and LC–MS analysis for peptide mapping.** A reduced antibody sample was prepared with 0.05 M acetic acid and 0.05 M tris(2-carboxyethyl) phosphate hydrochloride in aqueous solution (the concentration of the antibody, 10 mg mL⁻¹), and then the solution was stirred at 75 °C for 15 min. The antibody solution was passed through the Pep-SpM at 10 or 100 mL h⁻¹, and the eluted solution was collected during every 1 min. On the other hand, the reduction antibody solution was also reacted with a pepsin solution as the comparison for 1 or 150 min. Both the collected fraction by online digestion in the Pep-SpM and by treating in solution were analyzed typical LC. LC conditions are follows; column, AdvanceBio PeptideMap 2.1 × 150 mm; mobile phase, 0.1 vol% TFA in water as mobile phase A and 0.1 vol% TFA in MeCN, 0 to 55% B for 0 to 30 min, 100% B for 30.1 to 40 min; temperature, 50 °C; flow rate, 0.2 mL min⁻¹, which is corresponding to Fig. 2(a) using UV detection. For LC–MS analyses, instead mobile phase condition was follows; 0.1 vol% TFA in water as mobile phase A and 0.1 vol% TFA in 90% MeCN aqueous, 0 to 43% B for 5 to 120 min, 100% B for 120.1 to 135 min, which is corresponding to Fig. 2(b,c) and Supplementary Table 1 obtained by PepFinder 2.0. The separated peaks were detected by a mass spectrometer, LTQ/XL Orbitrap (Thermo Fisher Scientific),
References

1. Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discovery 8, 226–234 (2009).

2. Weiner, G. J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15, 361–370 (2015).

3. Carter, P. J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343–357 (2006).

4. Reichert, J. M. & Valge-Archer, V. E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discovery 6, 349–356 (2007).

5. Moutel, S. & Perez, F. ‘Antibodies–Europe. Engineering the next generation of antibodies’. Biotechnol. J. 3, 298–300 (2008).

6. Weiner, L. M., Surana, R. & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317–327 (2010).

7. Ecker, D. M., Jones, S. D. & Levine, H. L. The therapeutic monoclonal antibody market. mAbs 7, 9–14 (2015).

8. Luo, Q., Zou, H., Zhang, Q., Xiao, X. & Ni, J. High-performance affinity chromatography with immobilization of protein A and L-histidine on modified monolith. Biotechnol. Bioeng. 80, 481–489 (2002).

9. Tscheliessnig, A. & Junghauer, A. High-performance monolith affinity chromatography for fast quantitation of immunoglobulin G. J. Chromatogr. A 1216, 2676–2682 (2009).

10. Thiel, K. A. Biom materializing. From bust to boom...to bubble? Nat. Biotechnol. 22, 1365–1372 (2004).

11. Farid, S. S. Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B 848, 8–18 (2007).

12. Love, J. C., Love, K. R. & Barone, P. W. Enabling global access to high-quality biopharmaceuticals. Curr. Opin. Chem. Eng. 2, 383–390 (2013).

13. Fawcett, R. L., Whitney, D. H., Vanderlaan, M. & Blank, G. S. Performance comparison of Protein A affinity-chromatography sorbents for purifying recombinant monoclonal antibodies. Biotechnol. Appl. Biochem. 30, 121–128 (1999).

14. Hahn, K., Schlegel, R. & Junghauer, A. Comparison of protein A affinity sorbents. J. Chromatogr. B 790, 35–51 (2003).

15. Rathore, A. S., Pathak, M., Ma, G. & Bracey, D. G. Re-use of protein A Resin: Felding and Economics. Biopharm Int. 28, 28–33 (2015).

16. Deisenhofer, J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å. ANG. resolution. Biochemistry 20, 2361–2370 (1981).

17. Junghauer, A. & Hahn, R. Engineering protein A affinity chromatography. Curr. Opin. Drug Discov. Devel. 7, 248–256 (2004).

18. Shukla, A. A., Hubbard, B., Tressel, T., Guhan, S. & Low, D. Downstream processing of monoclonal antibodies—application of platform approaches. J. Chromatogr. B 848, 28–39 (2007).

19. Perez-Almodovar, E. X. & Carta, G. IgG adsorption on a new protein A adsorbent based on macroporous hydrophilic polymers. J. Adsorption equilibrium and kinetics. J. Chromatogr. A 1216, 8339–8347 (2009).

20. Pollman, D. K. & Fawcett, R. L. Factorial screening of antibody purification processes using three chromatography steps without recent analytical applications. J. Chromatogr. A 1216, 79–85 (2004).

21. Przybycin, T. M., Pujar, N. S. & Steele, I. M. Alternative bioseparation operations: life beyond packed-bed chromatography. Curr. Opin. Biotechnol. 15, 469–478 (2004).

22. Kelley, B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol. Prog. 23, 995–1008 (2007).

23. Guillermate, D., Ruta, J., Rudaz, S. & Veuthey, J. L. New trends in fast and high-resolution liquid chromatography: a critical comparison of existing approaches. Anal. Bioanal. Chem. 397, 1069–1082 (2010).

24. van de Meent, M. H. M. & de Jong, G. J. Novel liquid-chromatography columns for proteomics research. Trac-Trend. Anal. Chem. 30, 1809–1818 (2011).

25. Chao, T. C. & Hansmeier, N. Microparticulate fluids for high throughput proteome analyses. Proteomics 13, 467–479 (2013).

26. Svec, F. Preparations and HPLC applications of rigid macroporous organic polymer monoliths. J. Sep. Sci. 27, 747–766 (2004).

27. Svec, F. Porous polymer monoliths: amazingly wide variety of techniques enabling their preparation. J. Chromatogr. A 1217, 902–924 (2010).

28. Teda, K. K. & van Beek, T. A. Bioaffinity chromatography on monolithic supports. J. Sep. Sci. 33, 422–438 (2010).

29. Flamm, B., Schleifenbaum, M., Dux, K., M. & Hage, D. S. Affinity monolith chromatography: a review of principles and recent analytical applications. Anal. Bioanal. Chem. 405, 2133–2143 (2013).

30. Tang, S. et al. Nanoparticle-based monoliths for chromatographic separations. Analyst 139, 4103–4117 (2014).

31. Feil, A., Elasser, M. S. & Husing, N. Sol-gel synthesis of monolithic materials with hierarchical porosity. Chem. Soc. Rev. 45, 3377–3399 (2016).

32. Watanabe, F., Kubo, T., Kaya, K. & Hossoya, K. Novel separation medium spongy monolith for high throughput analyses. J. Chromatogr. A 1216, 7402–7408 (2009).

33. Kubo, T., Tanigawa, T., Tomina, Y., Hossoya, K. & Otsuka, K. Rapid separations by LC using ion-exchange media based on spongy monoliths. J. Sep. Sci. 36, 2813–2818 (2013).

34. Ng, E. S., Chan, N. W., Lewis, D. F., Hindsaul, O. & Schriemer, D. C. Frontal affinity chromatography—mass spectrometry. Nat. Protoc. 2, 1907–1917 (2007).

35. Tada, H., Nakamura, Tsuruta, S. & Hiramatsu, A. Frontal affinity chromatography: sugar–protein interactions. Nat. Protoc. 2, 2529–2537 (2007).

36. Giddings, J. C. Dynamics of chromatography: principles and theory (CRC Press, 2002).

37. Kubo, T., Watanabe, F., Kaya, K. & Hossoya, K. High Throughput On-line Preconcentration Using ‘Spongy-monolith’ Prepared by Pore Temptates. Chem. Lett. 37, 950–951 (2008).

38. Tanigawa, T., Kato, K., Watabe, Y., Cubo, T. & Hossoya, K. Retention properties of macroporous spongy monolith and its application for concentration of polymeric hydrocarbons. J. Sep. Sci. 34, 2193–2198 (2011).

39. Beck, A., Wagner-Roussel, E., Ayoub, D., Van Dorselaer, A. & Sanglier-Cianferani, S. Characterization of therapeutic antibodies and related products. Anal. Chem. 85, 715–736 (2012).

40. Fekete, S., Guillermate, D., Sandra, P. & Sandra, K. Chromatographic, electrophoretic, and mass spectrometric methods for the analytical characterization of protein biopharmaceuticals. Anal. Chem. 88, 480–507 (2015).

41. Fekete, S., Gasser, A. L., Rudaz, S., Schappeler, J. & Guillermate, D. Analytical strategies for the characterization of therapeutic monoclonal antibodies. TrAC Trends Anal. Chem. 42, 74–83 (2013).

42. Pang, Y., Wang, W. H., Reid, G. E., Hunt, D. F. & Bruening, M. L. Pepsin-Containing Membranes for Controlled Monoclonal Antibody Digestion Prior to Mass Spectrometry Analysis. Anal. Chem. 87, 10942–10949 (2015).
Acknowledgements
This research was partly supported by the Grant-in Aid for Scientific Research (15K13756) from the Japan Society for the Promotion of Science, Shimadzu Science Foundation, and Kurita Water and Environment Foundation.

Author Contributions
Experiments were designed by T. Kubo, T. Naito, and K. Otsuka. The spongy monoliths were prepared by T. Tanigawa. The Chromatographic evaluations were operated by K. Kubota, and T. Kubo. The manuscript was written by T. Kubo, K. Kubota, and K. Otsuka.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-00264-y

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017